Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abatacept/golimumab

Abatacept/golimumab Reactions 1704, p13 - 2 Jun 2018 Various toxicities: 2 case reports A 70-year-old woman developed hepatosplenic bartonella infection during treatment with abatacept, and a 23-year-old woman developed cat scratch disease (CSD), Fusobacterium necrophorum infection and Lemierre syndrome during treatment with golimumab [dosages, routes, durations of treatments to reactions onsets not stated]. The 70-year-old woman, who received treatment with abatacept for the treatment of rheumatoid arthritis, presented with fever for 3 weeks. Laboratory results showed a WBC 3 3 count of 3100 /mm , platelet count of 58000 /mm and haemoglobin of 8.7 g/dL. An MRI scan of the abdomen showed splenomegaly with multiple focal abscesses. She had recently adopted a kitten. Serology was positive for B. henselae with an IgG titer of 1/10240. On liver biopsy, necrotising granulomatous hepatitis was observed along with positive Warthin-Starry staining. A diagnosis of hepatosplenic bartonella infection was confirmed by a positive PCR. Her treatment with abatacept was withdrawn. She was treated with rifampicin, azithromycin and doxycycline. After 4 weeks complete clinical improvement was observed. The 23-year-old woman, who received treatment with golimumab for the treatment of ankylosing spondylitis, presented with fever and a large left cervical lymphadenopathy for 2 days. Multiple enlarged http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Abatacept/golimumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Abatacept/golimumab

Abstract

Reactions 1704, p13 - 2 Jun 2018 Various toxicities: 2 case reports A 70-year-old woman developed hepatosplenic bartonella infection during treatment with abatacept, and a 23-year-old woman developed cat scratch disease (CSD), Fusobacterium necrophorum infection and Lemierre syndrome during treatment with golimumab [dosages, routes, durations of treatments to reactions onsets not stated]. The 70-year-old woman, who received treatment with abatacept for the treatment of rheumatoid arthritis,...
Loading next page...
1
 
/lp/springer_journal/abatacept-golimumab-lXYqXmS5Bu

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46656-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p13 - 2 Jun 2018 Various toxicities: 2 case reports A 70-year-old woman developed hepatosplenic bartonella infection during treatment with abatacept, and a 23-year-old woman developed cat scratch disease (CSD), Fusobacterium necrophorum infection and Lemierre syndrome during treatment with golimumab [dosages, routes, durations of treatments to reactions onsets not stated]. The 70-year-old woman, who received treatment with abatacept for the treatment of rheumatoid arthritis, presented with fever for 3 weeks. Laboratory results showed a WBC 3 3 count of 3100 /mm , platelet count of 58000 /mm and haemoglobin of 8.7 g/dL. An MRI scan of the abdomen showed splenomegaly with multiple focal abscesses. She had recently adopted a kitten. Serology was positive for B. henselae with an IgG titer of 1/10240. On liver biopsy, necrotising granulomatous hepatitis was observed along with positive Warthin-Starry staining. A diagnosis of hepatosplenic bartonella infection was confirmed by a positive PCR. Her treatment with abatacept was withdrawn. She was treated with rifampicin, azithromycin and doxycycline. After 4 weeks complete clinical improvement was observed. The 23-year-old woman, who received treatment with golimumab for the treatment of ankylosing spondylitis, presented with fever and a large left cervical lymphadenopathy for 2 days. Multiple enlarged

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.